BioSpace News Archive

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update.

Daxor Corporation, the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on February 28, 2022, disclosing its schedule of portfolio holdings as of December 31, 2021.

TFF Pharmaceuticals, Inc. and Catalent announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals’ patented Thin Film Freezing technology.

ProKidney LP announced that Joseph Stavas, MD, MPH, Senior Vice President of Clinical Development, will present data on the Company’s lead product candiate, Renal Autologous Cell Therapy at the 4th Annual CKD Summit, being held March 1-3, 2022 in Boston, MA.

AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update from the Type C guidance meeting with the U.S. Food and Drug Administration (“FDA”) regarding the development path for LPCN 1144.

Innovative rhPSMA Theranostic technology has the potential to offer both diagnostic imaging and treatment for patients affected by prostate cancer.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results.

Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced a study was published on-line as a pre-proof in the peer-reviewed Journal of Vascular Surgery with data collected using QuantaFlo® under real-world conditions.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2021.